Mauna Kea Technologies
Mauna Kea Technologies (Paris, Euronext Growth Paris: ALMKT) designs and commercializes the Cellvizio platform, a probe-based confocal laser endomicroscopy system providing real-time in vivo cellular imaging for gastroenterology, pulmonology, and urology, selling systems and consumables to hospitals and academic medical centers worldwide.
- Company typePublic
- Founded2000
- HeadquartersParis, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mauna Kea Technologies does
Mauna Kea Technologies is a Paris-based, publicly listed (Euronext Growth Paris: ALMKT) medical device company founded in 2000 by astrophysicist Sacha Loiseau, commercializing the Cellvizio platform — the first commercial real-time, in vivo cellular imaging system based on probe- and needle-based Confocal Laser Endomicroscopy (CLE). The platform works through confocal miniprobes (CholangioFlex, ColoFlex UHD, GastroFlex UHD, AQ-Flex 19) inserted into the working channel of standard endoscopes to deliver cellular-level visualization during procedures in gastroenterology, pulmonology, and urology. The technology originated from research at NASA's Jet Propulsion Laboratory and is supported by 1,300+ clinical papers and 20 FDA clearances.
The company operates a hybrid razor-and-blade business model combining capital equipment sales (Cellvizio systems, including the next-generation Gen 3) with recurring consumable revenue from disposable miniprobes, supplemented by tailored multi-year service contracts. Go-to-market is direct enterprise sales in the US (Allston, MA office) and France, with a worldwide distributor network covering 17+ countries across EMEA, APAC, and select LATAM markets. Customer base consists primarily of academic medical centers and hospital systems (e.g., Mayo Clinic, University Hospital Basel, Bern University Hospital, Amsterdam UMC). Beyond the core platform, Mauna Kea has built the CellTolerance consumer-pay diagnostic program for IBS/food intolerance (€1M sales in 2025) and pursues strategic co-development partnerships with Johnson & Johnson, Telix Pharmaceuticals (19.33% shareholder), and TaeWoong Medical to extend the technology into urologic oncology, AI-assisted imaging, and pancreatic cyst management.
In 2024, total sales were €7.6 million; the company completed a financial restructuring in November 2025 that reduced debt from €40M to €12M and extended cash runway to H2 2027. Q1 2026 core sales grew +68% at constant exchange rates, and the first half of 2026 added regulatory approvals in the UAE, Turkey, Switzerland, and the UK, plus CE MDR certification for Cellvizio, supporting an accelerating growth trajectory.
Mauna Kea Technologies firmographics
Firmographics- Name
- Mauna Kea Technologies
- Legal name
- Mauna Kea Technologies
- Website
- https://maunakeatech.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Mauna Kea Technologies (Paris, Euronext Growth Paris: ALMKT) designs and commercializes the Cellvizio platform, a probe-based confocal laser endomicroscopy system providing real-time in vivo cellular imaging for gastroenterology, pulmonology, and urology, selling systems and consumables to hospitals and academic medical centers worldwide.
- Ownership category
- akta.pro rank
Mauna Kea Technologies industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)
- akta.pro secondary industries
- Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where Mauna Kea Technologies is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Mauna Kea Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
Revenue model
- Cellvizio System Sales: Sale of Cellvizio imaging systems to healthcare institutions and hospitals
- Confocal Miniprobes (Consumables): Sale of disposable confocal miniprobes used during procedures - represents recurring revenue stream from consumables
- Service Contracts: Tailored service contracts including preventative maintenance, software upgrades, on-site maintenance, loaner service, and predictive maintenance
- CellTolerance Program: Food intolerance diagnostic program using Cellvizio reached €1 million in sales in 2025, representing new revenue stream
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Cellvizio Service Contract - customized maintenance and support packages |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Mauna Kea Technologies product offering
Product offeringCore offering
Mauna Kea Technologies designs, develops, manufactures, and sells the Cellvizio platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy (CLE) technology. The platform uses disposable Confocal Miniprobes inserted through standard endoscopes or biopsy needles to deliver cellular-level visualization during gastroenterology, pulmonology, and urology procedures, sold to hospitals, academic medical centers, and specialty clinics as a system-plus-consumables model with associated service contracts.
Product overview
Mauna Kea Technologies offers the Cellvizio® platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy technology. The platform serves multiple medical specialties (gastroenterology, pulmonology, urology) through a modular approach: the core Cellvizio® system works with specialized Confocal Miniprobes™ (CholangioFlex™, ColoFlex™ UHD, GastroFlex™ UHD, AQ-Flex™ 19) designed for different anatomical regions and procedures. The company has developed CellTolerance®, a diagnostic application powered by Cellvizio for food intolerance testing in IBS patients. The portfolio includes the latest Cellvizio Gen 3 system and spans clinical indications such as pancreatic cysts, Barrett's esophagus, colorectal lesions, inflammatory bowel disease, lung nodules, and urologic applications.
Differentiator
Problem solved
Functional benefit
Brands
- Cellvizio: The real-time in vivo cellular imaging platform using Confocal Laser Endomicroscopy (CLE) technology for cellular visualization across multiple medical specialties.
- CellTolerance
- C-FIT
Products and services
- Cellvizio Real-time in vivo cellular imaging platform using probe-based and needle-based Confocal Laser Endomicroscopy (pCLE/nCLE) that delivers cellular visualization virtually anywhere in the human body through Confocal Miniprobes inserted into standard endoscopes. Sold to hospitals, gastroenterologists, pulmonologists, and urologists.
- Cellvizio Gen 3 System Next-generation version of the Cellvizio platform with enhanced imaging capabilities for real-time in vivo cellular visualization. Received CE MDR certification and regulatory approvals across multiple jurisdictions including UAE, Turkey, Switzerland, and the UK.
- CholangioFlex Miniprobe Disposable confocal miniprobe for real-time imaging of biliary and pancreatic ducts during ERCP procedures, enabling in vivo characterization of bilio-pancreatic strictures. Sold as a consumable to gastroenterology departments.
- ColoFlex UHD Miniprobe Ultra-high definition disposable confocal miniprobe for assessment of colorectal lesions during colonoscopy, enabling differentiation between neoplastic and non-neoplastic tissue. Sold as a consumable to gastroenterology departments.
- GastroFlex UHD Miniprobe Ultra-high definition disposable confocal miniprobe for gastrointestinal tract imaging, used in procedures for gastric disease, Barrett's esophagus, and inflammatory bowel disease assessment. Sold as a consumable to gastroenterology departments.
- AQ-Flex 19 Miniprobe Needle-based disposable confocal miniprobe for lung lesion characterization, deployed through biopsy needles during EBUS-TBNA, EUS-FNA, and TBNA procedures for real-time diagnosis of peripheral lung nodules. Sold as a consumable to pulmonology departments.
- CellTolerance Program Multidisciplinary diagnostic program powered by Cellvizio for identifying food intolerances associated with Irritable Bowel Syndrome through real-time visualization of live cell response during endoscopy procedures (C-FIT test). Reached €1 million in sales in 2025 and is targeted at GI clinics serving IBS patients.
- Cellvizio Service Contracts Tailored multi-year service contracts for Cellvizio systems including preventative maintenance, regular software upgrades, on-site maintenance, loaner service, log files-based predictive maintenance, and on-demand technical support. Sold to existing Cellvizio system customers.
Quantifiable outcome
- 100% relapse-free rate over 24 months for UC patients achieving triple healing (0 of 29), vs ~33% relapse rate in non-achievers
- +6 more outcomes
Companies that use Mauna Kea Technologies
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles2 records
Mauna Kea Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Mauna Kea Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- TaeWoong Medical USAmajorExclusive partnership to integrate Cellvizio with TaeWoong's EUS-guided therapeutic devices in the US. Creates comprehensive pancreatic cyst management solution combining imaging with therapy. Aims to streamline workflow, improve diagnostic accuracy, and enhance patient care for pancreatic conditions.
- Johnson & JohnsoncoreStrategic collaboration with Johnson & Johnson expanding reach of Cellvizio technology in gastroenterology and other therapeutic areas including robotics surgery and AI-assisted imaging.
- MetrodoracorePartnership to create first U.S. Center of Excellence for the use of Cellvizio to identify and treat food intolerance in adults.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
Mauna Kea Technologies competitors and assessment
Company assessmentBroad incumbents
- Olympus Corporation: Global leader in endoscopy systems and accessories across GI, pulmonology, and urology. Competes with Cellvizio as the dominant platform on which miniprobes are inserted, and could integrate comparable cellular imaging into its ecosystem.
- Boston Scientific: Major medtech player with significant endoscopy, pulmonology, and urology franchises. Overlaps with Cellvizio in interventional pulmonology and urology, and has scale advantages in procedure-enabling devices.
- HOYA Corporation (Pentax Medical): Endoscopy systems and accessories manufacturer. Directly comparable as the supplier of endoscopes through which Cellvizio miniprobes operate, and a potential integrator of cellular imaging.
- Fujifilm Healthcare: Endoscopy systems provider with growing presence in GI imaging and AI-assisted endoscopy. Competes broadly with Cellvizio in gastroenterology procedure suites.
- KARL STORZ SE & Co. KG: Endoscopy manufacturer serving pulmonology, urology, and GI. Comparable as an endoscopy systems provider that competes for hospital capital budgets and could integrate probe-based imaging.
- Medtronic: Diversified medtech incumbent with GI, pulmonology, and urology franchises. Overlaps with Cellvizio across multiple procedure types and at large hospital IDNs.
- Stryker Corporation: Medical device major with endoscopy and surgical visualization offerings. Competes for hospital capital across the same procedure suites where Cellvizio is deployed.
- Intuitive Surgical: Surgical robotics and visualization leader. Strategic overlap with Cellvizio's stated expansion into robotics surgery and AI-assisted imaging through its Johnson & Johnson partnership.
Direct peers
- NinePoint Medical (NvisionVLE Imaging): Probe-based optical coherence tomography imaging during endoscopy, the closest direct competitor to Cellvizio's in vivo probe-based cellular imaging approach in GI.
Others
- Johnson & Johnson (MedTech): Strategic partner (JJDC investor and Cellvizio collaboration partner) with overlapping GI and surgical visualization interests. Relevant as both partner and potential acquirer/competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Mauna Kea Technologies social profiles
Digital presenceMauna Kea Technologies compliance and trust
Trust signalCompliance3 records
Mauna Kea Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mauna Kea Technologies leadership team
Management profileNumber of profiles
Profiles12 records
Mauna Kea Technologies funding detail
Funding detailFunding overview
Funding rounds8 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mauna Kea Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mauna Kea Technologies
What does Mauna Kea Technologies do?
Mauna Kea Technologies designs, develops, manufactures, and sells the Cellvizio platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy (CLE) technology. The platform uses disposable Confocal Miniprobes inserted through standard endoscopes or biopsy needles to deliver cellular-level visualization during gastroenterology, pulmonology, and urology procedures, sold to hospitals, academic medical centers, and specialty clinics as a system-plus-consumables model with associated service contracts.
Is Mauna Kea Technologies a public or private company?
Mauna Kea Technologies is a public company. It is classified as public and is currently operating.
When was Mauna Kea Technologies founded?
Mauna Kea Technologies was founded in 2000. It employs 101 to 250 people.
Where is Mauna Kea Technologies based?
Mauna Kea Technologies is headquartered in Paris, France, in the Europe region.
How does Mauna Kea Technologies make money?
Four revenue lines are on record. Cellvizio System Sales are the primary driver. The others are confocal Miniprobes (Consumables), service Contracts and cellTolerance Program.
Who are Mauna Kea Technologies's main competitors?
Broad incumbents on record are Olympus Corporation, Boston Scientific, HOYA Corporation (Pentax Medical), Fujifilm Healthcare, KARL STORZ SE & Co. KG, Medtronic, Stryker Corporation and Intuitive Surgical. NinePoint Medical (NvisionVLE Imaging) is listed as a direct peer. Johnson & Johnson (MedTech) is listed as an others.
Does Mauna Kea Technologies have an API?
No public API is recorded for Mauna Kea Technologies.
What industry is Mauna Kea Technologies in?
Mauna Kea Technologies's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation), with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.